(Q35577787)

9 August 2017

1 reference

title

An overview of proton pump inhibitors (English)

1 reference

9 August 2017

An Overview of Proton Pump Inhibitors (English)

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

29 March 2024

author name string

Gabriella Der

1

1 reference

9 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14603076

29 March 2024

publication date

1 September 2003

1 reference

full work available at URL

9 August 2017

http://journals.lww.com/00001610-200309000-00003

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

29 March 2024

published in

Gastroenterology Nursing

1 reference

9 August 2017

26

1 reference

9 August 2017

5

1 reference

9 August 2017

182-190

1 reference

Omeprazole and ultrastructural modifications occurring in reflux esophagitis

9 August 2017

1

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials

29 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

29 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics

29 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

29 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology

29 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression

29 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Lansoprazole for maintenance of remission of erosive oesophagitis

29 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole

29 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

The proton-pump inhibitors: similarities and differences

29 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial

29 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease

29 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Randomized comparative study of omeprazole and famotidine in reflux esophagitis

29 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

29 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa

29 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers

29 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.

29 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

29 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Brazilian consensus on gastroesophageal reflux disease: proposals for assessment, classification, and management

29 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Intravenous proton pump inhibitors in the critical care setting

29 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis

29 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition.

29 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Cleveland Clinic Journal of Medicine

29 March 2024

26

67

758

Ramirez

2000

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Safety profile of the proton-pump inhibitors.

29 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group

29 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients

29 March 2024

30

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Triple therapy with lansoprazole, clarithromycin, and amoxicillin for the cure of Helicobacter pylori infection: a short report

29 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis

29 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials

29 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens

29 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Restoration of acid secretion following treatment with proton pump inhibitors

29 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

The Journal of Rheumatology

29 March 2024

36

29

1501

Simon

2002

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Dyspepsia management in primary care: a decision analysis of competing strategies.

29 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Sporadic fundic gland polyposis: a clinical, histological, and molecular analysis

29 March 2024

39

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Fundic gland polyps are not induced by proton pump inhibitor therapy

29 March 2024

41

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies

29 March 2024

42

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

29 March 2024

44

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

Critical review of acid suppression in nonvariceal, acute, uppergastrointestinal bleeding

29 March 2024

45

1 reference

https://api.crossref.org/works/10.1097/00001610-200309000-00003

29 March 2024

Identifiers

1 reference

9 August 2017

1 reference